🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

39 results for “Essential” Clear

  1. QGC001

    Quantum Biopharma

    Essential Hypertension

    phase 2 small molecule completed

    1 trial

  2. Recombinant Interferon Alpha

    China SXT Pharmaceuticals

    Essential Thrombocytopenia

    phase 2 small molecule active

    2 trials

  3. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  4. anagrelide hydrochloride

    Takeda Pharmaceuticals International AG

    Essential Thrombocythaemia

    phase 2 small molecule completed

    1 trial

  5. A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia

    Incyte Biosciences Distribution B.V.

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  6. An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with High Risk Essential Thrombocythaemia who are Resistant to or Intolerant of Hydroxycarbamide Therapy. The VECTRA Study

    Pharma Mar S.A.

    Thrombocythaemia

    phase 1 other active

    1 trial

  7. QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]

    Quantum Biopharma

    Essential Hypertension

    phase 1 small molecule completed

    2 trials

  8. SENTI-202

    Essential Pharma Limited

    AML/MDS

    phase 1 mab active

    1 trial

  9. SN301A

    Essential Pharma Limited

    Hepatocellular Carcinoma (HCC)

    phase 1 mab active

    1 trial

  10. Azilsartan

    Takeda Pharmaceuticals International AG

    Essential Hypertension Complicated by Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  11. Azilsartan

    Takeda Pharmaceuticals International AG

    Essential Hypertension With Stable Angina and Dyslipidemia

    approved small molecule terminated

    1 trial

  12. Azilsartan Medoxomil

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    approved small molecule completed

    2 trials

  13. Songling Xuemaikang Capsules

    China SXT Pharmaceuticals

    Hypertension,Essential

    approved small molecule active

    1 trial

  14. Essential Amino Acid Enriched Whey Protein

    United Therapeutics Europe Ltd

    Whole-body Protein Balance

    other completed

    1 trial

  15. Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases

    China SXT Pharmaceuticals

    Hypertension,Essential

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources